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Comparison of clinical characteristics and outcomes between 
COVID-19 pneumonia and H1N1 influenza
Abstract
Introduction: The COVID-19 pandemic has been likened to the 2009 H1N1 influenza pandemic. We aim to study the similarities 
and differences between patients hospitalized with COVID-19 and H1N1 influenza in order to provide better care to patients, 
particularly during the co-circulation of Influenza A Subtype H1N1 and SARS-CoV-2. 
Material and methods: A retrospective cohort study was conducted in order to compare clinical characteristics, complications, 
and outcomes of hospitalized patients with PCR-confirmed H1N1 influenza pneumonia and COVID-19 at a tertiary care center in 
Karachi, Pakistan. 
Results: A total of 115 patients hospitalized with COVID-19 were compared with 55 patients with H1N1 Influenza A pneumonia. 
Median age was similar in both COVID-19 patients (54 years) and in patients with H1N1 influenza (59 years), but there was 
male predominance in COVID-19 patients (OR = 2.95; 95% CI: 1.12–7.79). Patients with COVID-19 pneumonia were 1.34 (95% 
CI: 1.14–1.62) times more likely to have a greater duration of illness prior to presentation compared to H1N1 influenza patients. 
COVID-19 patients were 4.59 times (95% CI: 1.32–15.94) more likely to be admitted to a general ward compared to H1N1 pneu-
monia patients. Moreover, patients with COVID-19 were 7.62 times (95% CI: 2.42–24.00) more likely to be treated with systemic 
steroids compared to patients with H1N1 pneumonia. The rate of nosocomial infections as well as mortality was similar in both 
H1N1 and COVID-19 pneumonia.
Conclusion: Our study found a male predominance and longer duration of illness in hospitalized patients with COVID-19 compared 
to H1N1 influenza patients but no difference in outcomes with either infection. 
Key words: COVID-19, influenza A subtype H1N1, pneumonia
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Introduction
The COVID-19 pandemic, which initially 
started as an outbreak in the city of Wuhan in Chi-
na, has presently infected more than 100 million 
people worldwide and has an estimated mortality 
of greater than 2 million [1]. Immediately after the 
pandemic was announced by the World Health 
Organization in March 2020, comparisons were 
drawn with the H1N1 Influenza A pandemic of 
2009. In April 2009, numerous cases of severe 
pneumonia and influenza-like illness were re-
ported by Mexican public health authorities in 
the town of La Gloria in the state of Veracruz. 
Shortly afterwards, similar cases were reported 
in California in the United States [2]. It was soon 
discovered that a new strain of the swine-origin 
influenza A (H1N1) flu had appeared in these 
countries. By the end of May 2009, 41 countries 
had reported 11,000 cases and 85 deaths and the 
WHO declared its first “Public Health Emergen-
cy of International Concern” (PHEIC) [3]. The 
2009 swine flu pandemic lasted from January 
2009 to August 2010 and was reported by the 
WHO to have caused nearly 18,500 deaths globally 
[3]. At present, worldwide cases of influenza-asso-
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ciated respiratory mortality have been occurring 
at a higher rate than what has been previously 
recorded [4]. According to CDC estimates, between 
April 2009 and April 2010, there were 60.8 million 
cases of H1N1 Influenza in the United States, with 
12,500 deaths and a case fatality rate of 0.02% [5]. 
This is in contrast to the mortality rates reported 
with SARS-CoV-2 which have remained greater 
than 2% in most parts of the world [1]. Moreover, 
while the 2009 H1N1 pandemic caused deaths 
among primarily the young population, the ma-
jority of deaths in COVID-19 have occurred among 
the elderly [6].
Both the influenza virus and SARS-CoV-2 
have similar modes of transmission (i.e. droplet 
and direct contact) but the incubation periods 
and rate of transmissibility differ significantly 
with SARS-CoV-2 having a longer duration of 
incubation and increased transmissibility [7]. The 
mechanism of viral pneumonia in COVID-19 is 
multifaceted with studies indicating that the viral 
infection is capable of producing an excessive 
immune reaction in the host. In some cases, there 
is extensive tissue damage with dysfunctional 
coagulation, which is also classified as a “cytokine 
storm” and can result in acute respiratory distress 
syndrome (ARDS) and multi-organ failure leading 
to death [8]. However, although ARDS is frequent-
ly observed in influenza pneumonia [9], the case 
fatality rate is lower than that of COVID-19 [10]. 
Similar to COVID-19, the most commonly re-
ported symptoms of influenza included chills, 
cough, rhinorrhea, fever, sore throat, coryza, 
myalgia, shortness of breath, headache, dizziness, 
abdominal pain, decreased appetite, and malaise. 
The 2009 H1N1 strain also showed an increased 
number of people reporting vomiting and diarrhea 
as well [11, 12]. 
Although there have been some studies fo-
cusing on differences in symptomatology of sea-
sonal influenza viruses, there are limited studies 
comparing clinical manifestations and compli-
cations of COVID-19 and Influenza A subtype 
H1N1, which share common clinical presenta-
tions. It is expected that there will be seasonal 
overlap  of H1N1 Influenza A pneumonia and 
COVID-19 pneumonia, particularly between De-
cember and February. Hence, it is imperative to 
recognize the similarities and dissimilarities in 
order to provide better care to patients and identify 
those at increased risk for complications. Hence, 
we conducted this study to determine differenc-
es in clinical manifestations and complications 
between patients with H1N1 Influenza A pneu-
monia and COVID-19 requiring hospitalization at 
a tertiary care, academic medical center in Karachi 
Pakistan with a dedicated COVID-19 facility.
Material and methods
Study population and design
We conducted a retrospective cohort study 
of adult patients hospitalized with a RT-PCR-con-
firmed diagnosis of H1N1 Influenza pneumonia 
during seasonal outbreaks between the years 
2017 and 2019 and patients hospitalized with 
RT-PCR confirmed COVID-19 during the outbreak 
from March 2020 onwards in a 700 bed tertiary 
care hospital in Karachi, Pakistan. Demographic 
and clinical characteristics of H1N1 influenza 
patients and COVID-19 patients including under-
lying medical and respiratory comorbidities, lab-
oratory and radiological investigations, treatment, 
and complications during hospitalization were 
collected from hospital information management 
systems on a structured proforma. 
Diagnosis of H1N1 influenza A 
and SARS-CoV-2
Nasopharyngeal swabs were processed for de-
tection of the influenza virus by real-time reverse 
transcriptase polymerase chain reaction (RT-PCR) 
using the influenza virus PCR assay (Altona Di-
agnostics, GmbH). Nasopharyngeal swabs were 
processed for detection of SARS-CoV-2  virus by 
real-time reverse transcriptase polymerase chain 
reaction (RT-PCR) using the WHO protocol for the 
2019 nCoV RT-PCR assay in March 2020. In May 
2020, specimens were tested using the Cobas® 
SARS-CoV-2  RT-PCR assay (Roche Diagnostics, 
USA). A radiological diagnosis of pneumonia 
was made by evaluation of infiltrates observed on 
chest radiographs and/or CT of the chest. A multi-
disciplinary team of doctors including infectious 
disease consultants, pulmonologists, and internal 
medicine specialists were involved in the identi-
fication of cases and their management.
Ethical approval
This study received approval from the Aga 
Khan University Ethics Review Committee (ERC 
Reference Number: 2020-4908-10926). The re-
quirement for informed consent was waived by 
the hospital ethics review committee as data was 
anonymized and no personal identifiers were 
collected.
Data analysis
We compared hospitalized H1N1 influenza 
patients with COVID-19 patients at a ratio of 1:2 in 
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order to improve statistical efficiency. Descriptive 
analysis was performed for demographic features 
with medians and interquartile ranges reported 
for quantitative variables such as age and length 
of hospital stay, as well as for frequencies (per-
centage) of qualitative variables such as gender, 
comorbid conditions, mortality, complications 
etc. The χ2 test of independence or the Fisher ex-
act test was performed in order to compare factors 
between those with H1N1 influenza and those 
with COVID-19 pneumonia. Multivariable logis-
tic regression analysis was performed in order to 
identify factors associated with COVID-19 pneu-
monia compared with H1N1 influenza. Subgroup 
analysis was performed using the Fisher exact 
test in order to compare those who died from 
COVID-19 to those who died from H1N1 influen-
za. STATA ver. 12.1 was used for data analysis and 
a p value ≤ 0.05 was considered to be significant.
Results
A total of 55 patients with H1N1 influenza 
A pneumonia were compared with 115 patients 
with COVID-19 who required hospitalization. The 
median age was similar in both COVID-19 patients 
(54 years) and in patients with H1N1 influenza 
(59 years). In COVID-19 patients, there was a male 
predominance with a male to female ratio of 3.26; 
the male to female ratio in H1N1 pneumonia was 
0.66 (p < 0.001). Disaggregated data was evaluated 
for both COVID-19 and H1N1 influenza patients 
to determine gender differential across different 
age groups (Figure 1). Among H1N1 influenza 
patients, there were predominantly more females 
among younger age groups, but the male to female 
ratio became similar in patients with advanced age 
(p = 0.036). Overall, there were more females than 
males. On the other hand, in COVID-19 patients, 
there was a male predominance throughout all 
age groups (p = 0.016). The median duration 
of illness prior to presentation was 7 days (IQR 
4–10) for COVID-19 compared to 5 days (IQR 3–5) 
for H1N1 influenza. The median CURB-65 Score 
was higher in patients with H1N1 influenza (p < 
0.001). The most frequent comorbid conditions 
in both groups were diabetes and hyperten-
sion. However, there was a significantly greater 
number of patients with asthma and COPD in 
the H1N1 influenza group (Table 1). In terms of 
radiological findings, bilateral lung infiltrates 
were most commonly found on chest radiographs 
in both groups. However, a comparatively high-
er number of patients presented with bilateral 
lung involvement in H1N1 pneumonia than 
those with COVID-19 pneumonia (92% vs 75%, 
p = 0.006). In terms of laboratory parameters, 
the median procalcitonin levels were similar 
but the median neutrophil to lymphocyte ratio 
(NLR) was slightly higher in patients with H1N1 in-
fluenza than in COVID-19 patients (6.84 vs 4.10, p 
= 0.077). However, the median CRP was higher in 
patients with COVID-19 pneumonia than in those 
with H1N1 pneumonia (72.6 vs 65, p = 0.347), 
although this was not statistically significant. 
The majority of patients with H1N1 pneumonia 
required admission to either a special care unit 
or intensive care unit as opposed to those with 
COVID-19 pneumonia (Table 2). Thirty-three per-
cent of patients with H1N1 pneumonia required 
invasive ventilation as compared to 15.6% with 
COVID-19 pneumonia (p = 0.011). All patients 
with H1N1 influenza received oseltamivir for 
treatment. Patients with COVID-19 were more like-
ly to be treated with systemic steroids compared 
to patients with H1N1 influenza (60% vs 40%, 
p = 0.014). 98% of patients with H1N1 influenza 
received antibiotics concomitantly compared to 
55% of patients with COVID-19. Among com-
plications, 40% of patients with H1N1 influenza 
had acute kidney injury compared to 20% of 
COVID-19 patients (p = 0.01). The rate of noso-
comial infections was similar in both H1N1 and 
COVID-19 pneumonia (n = 10 in COVID-19 and 
n = 8 in H1N1 influenza). In both groups, the most 
common organisms were multi-drug resistant 
Acinetobacter sp. (n = 6), Pseudomonas aeruginosa 
(n = 4), and methicillin-resistant Staphylococcus 
aureus (MRSA) (n = 4). Moreover, Aspergillus 
species were isolated in lower respiratory tract 
specimens of seven patients (n = 4 in the H1N1 in-
fluenza group and n = 3 in the COVID-19 group) 
with the most common species being Aspergillus 
flavus (6/7 patients). Mortality and length of hos-
pitalization was similar in both groups (Table 2).
In multivariable logistic regression analysis, 
it was found that patients with COVID-19 pneu-
monia were 1.34 (95% CI: 1.14–1.62) times more 
likely to have a greater duration of illness prior 
to presentation compared to H1N1 influenza pa-
tients. Moreover, there was a male predominance 
in COVID-19 (OR = 2.95; 95% CI: 1.12–7.79) com-
pared to H1N1 influenza pneumonia. Patients with 
COVID-19 were 4.59 times (95% CI: 1.32–15.94) 
more likely to be admitted to an inpatient setting 
compared to those with H1N1 pneumonia. Fur-
thermore, patients with COVID-19 pneumonia 
were 7.62 times (95% CI: 2.42–24.00) more likely 
to be treated with systemic steroids compared to 
H1N1 pneumonia patients.
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A subgroup analysis of mortality in patients 
in both groups showed that 12 out of 13 patients 
who died from COVID-19 were male, whereas 
mortality from H1N1 influenza was equally dis-
tributed (n = 5 each). The median age of mor-
tality in COVID-19 patients was 62 years (IQR: 
55–70) as compared to 56 years (IQR: 43–63) in 
patients with H1N1 influenza. The majority of 
patients from both groups had been admitted to 
the ICU and had required invasive ventilation 
(p < 0.001) prior to mortality. The cause of 
death was ARDS in the majority of those who 
died from both COVID-19 (11/13) and H1N1 in-
fluenza (9/10). Four out of 13 patients who died 
from COVID-19 and two out of 10 patients with 
H1N1 pneumonia also had a NSTEMI. Among all 
the patients who died in both groups, increases in 
NLR (p=0.013) and CRP (0.039) were significantly 
associated with mortality.
Discussion
Our study highlights similarities and differ-
ences between COVID-19 and H1N1 influenza 
pneumonia. There was a significant male predom-
inance amongst patients with COVID-19 which 
Figure 1. Gender differential by age group in COVID-19 pneumonia patients compared with H1N1 influenza patients
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is consistent with data reported from other parts 
of the world [13]. As opposed to this, there was 
almost equal gender distribution in H1N1 pneu-
monia [12]. Also, it was notable that hospitaliza-
tion was required in similar age groups for both 
infections. This is in contrast to earlier reports 
from the 2009 H1N1 pandemic where there was 
greater severity among younger age groups who 
developed infection with influenza A subtype 
H1N1 [5]. However, this is similar to the seasonal 
influenza outbreaks reported from different parts 
of the world where greater severity is observed 
in elderly populations [14]. In our study, there 
was a longer duration of illness prior to presen-
tation in patients with COVID-19 compared to 
H1N1 influenza patients. Tang et al. reported 
a similar difference of duration in patients re-
quiring hospitalization with COVID-19 patients 
having a relatively protracted course and becom-
ing critically ill later than those with influenza 
[15]. It has been postulated that this variance 
may be due to the difference in the distribution 
of virus entry receptors because the influenza 
A virus binds to α2, 6-linked sialic acid recep-
tors, expressed throughout the respiratory tract 
and likely responsible for the short incubation 
period. On the other hand, the receptor actively 
involved in SARS-CoV-2 is the ACE2 protein 
Table 1. Baseline characteristics of patients with COVID-19 pneumonia compared to H1N1 influenza A pneumonia
Characteristics COVID-19 (n = 115) H1N1 (n = 55) P value
Median age (IQR) in years 54 (43–65) 59 (36–65) 0.951
    Median CURB score (IQR) 1 (0–2) 2 (1–2) < 0.001
    Median Duration of Illness (IQR) in days 7 (4–10) 5 (3–5) < 0.001
Gender 
    Male







    Diabetes 43 (37.4) 24 (43.6) 0.436
    Hypertension 41 (35.7) 24 (43.6) 0.316
    COPD 0 (0.0) 8 (14.6) < 0.001
    Coronary artery disease 18 (15.7) 6 (10.9) 0.406
    Obesity 1 (0.9) 5 (0.1) 0.014
    CVA 4 (3.5) 2 (3.6) 0.958
    Malignancy 6 (5.2) 2 (3.6) 0.649
    Immunosuppression 1 (0.9) 4 (7.3) 0.038
    Asthma 1 (0.9) 7 (12.7) 0.002
    ILD 0 (0.0) 2 (3.6) 0.103
    CLD 3 (2.6) 1 (1.8) 0.750
    CKD 8 (6.9) 3 (5.4) 0.710
Radiological findings
    Unilateral 9 (7.9) 2 (3.6) 0.507
    Bilateral 86 (75.4) 51 (92.7) 0.006
Laboratory investigations
    Median procalcitonin (IQR) 0.129 (0.06–0.43) 0.74 (0.18–3.9) 0.564
    Median creatinine (IQR) 1 (0.8–1.3) 1.2 (0.9–1.5) 0.521
    Median CRP mg/L (IQR) 72.65 (21.83–179.87) 65.8 (23.2–152.1) 0.347
NLR
    < 3






CKD — chronic kidney disease; CLD — chronic liver disease; COPD — chronic obstructive pulmonary disease; CVA — cerebrovascular accident; ILD — interstitial 
lung disease; IQR — interquartile range
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Table 2. Outcomes and Complications of patients with COVID-19 pneumonia in comparison to patients with H1N1 
influenza A pneumonia
Variables COVID-19 (n = 115) H1N1 (n = 55) P value
Type of admission
    ICU 17 (14.8) 15 (27.3) 0.051
    SCU 42 (36.5) 30 (54.6) 0.026
    Ward 56 (48.7) 10 (18.2) < 0.001
Management
    Vasopressors 17 (14.8) 13 (23.6) 0.157
    Non-invasive ventilation 30 (26.1) 20 (36.4) 0.169
    Invasive ventilation 18 (15.6) 18 (32.7) 0.011
    Systemic steroids 69 (60.0) 22 (40.0) 0.014
    Antibiotics 63 (54.8) 54 (98.2) < 0.001
    Oseltamivir 1 (0.9) 55 (100.0) < 0.001
Complications
    ARDS 27 (23.5) 17 (30.9) 0.301
    Septic shock 16 (13.9) 13 (23.6) 0.115
    MODS 11 (9.6) 13 (23.6) 0.014
    Nosocomial infection 13 (11.3) 6 (10.9) 0.939
    AKI 24 (21.1) 22 (40.0) 0.01
    NSTEMI 10 (8.7) 9 (16.4) 0.138
Outcome
    Recovered 96 (88.1) 41 (80.4)
0.197    Mortality 13 (11.9) 10 (19.6)
    Unknown 6 (5.2) 4 (7.3)
    Median length of stay (IQR) 7 (4–10) 6 (4–10) 0.911
AKI — acute kidney injury; ARDS — acute respiratory distress syndrome; ICU — intensive care unit; SCU — special care unit; MODS — multi-organ dysfunction 
syndrome; NSTEMI — non-ST elevation myocardial infarction
predominantly found on alveolar epithelial cells 
which accounts for the longer incubation period 
of COVID-19 infection [16]. In the current study, 
almost all patients with H1N1 pneumonia and 
the majority of patients with COVID-19 had 
bilateral lung involvement on chest radiograph 
imaging at presentation. Studies have shown that 
although chest radiographs can be quite similar, 
computed tomography scans can show certain 
key differences such as the presence of pleural 
effusion and bronchiectasis in H1N1 influenza 
pneumonia that would otherwise not be seen 
during infection with COVID-19 [17, 18]. As 
opposed to H1N1, COVID-19 can present with 
normal chest radiographs as well as strictly 
unilateral chest involvement [19]. The study did 
not find any specific laboratory marker which 
was helpful in distinguishing between either 
infection and this is in agreement with previous 
studies published which compared the two in-
fections, although their amount is limited [20]. 
Serial monitoring of laboratory parameters such 
as serum procalcitonin, C-reactive protein, and 
neutrophil to lymphocyte ratio may be able to 
elicit differences as per the study conducted by 
Mei et al. [21] 
We found no difference in mortality 
in patients who required hospitalization for 
COVID-19 and H1N1 pneumonia. Studies have 
reported similar prognoses in patients with either 
infection [15]. The overall proportion of patients 
receiving systemic steroids was higher in both 
groups. However, patients with COVID-19 were 
more likely to be treated with steroids compared 
to H1N1 in our current study. This is also sim-
ilar to other studies reporting use of systemic 
steroids in the treatment of these infections [15]. 
As per the Cochrane review in 2019, a greater 
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number of patients with COVID-19 were treated 
with steroids as compared to influenza patients 
because  patients with influenza who received 
steroids as adjunctive treatment had a greater 
risk of mortality compared to those who did not 
receive steroid treatment. This was potentially 
due to the increased incidence of hospital-ac-
quired infections [22]. However, the RECOVERY 
trial for COVID showed mortality benefit with 
the use of steroids [23]. The immunosuppres-
sive effects of steroids may have implications 
on the development of nosocomial infections. In 
our study, patients developed these infections 
more often (11% of all patients) than those in 
other studies. Although the rate of nosocomial 
infections was similar in both groups, patients 
with H1N1 were more likely to be treated with 
antibiotics in addition to oseltamivir as opposed 
to COVID-19 patients, which is similar to other 
studies [24]. This study had some limitations. It 
was a single center, retrospective study. Howev-
er, to the best of our knowledge, it is the first to 
describe important common characteristics of 
both COVID-19 and H1N1 influenza infections 
and may be helpful in providing care to patients 
in the setting of these viral outbreaks. 
Conclusion
Our study highlights the difficulty in dis-
tinguishing these infections clinically. The only 
difference that stood out was the comparatively 
prolonged duration of illness prior to hospital-
ization in COVID-19 patients. Hence, patients 
may require screening with PCR in the set-
ting of an influenza-like illness to diagnose/rule 
out  influenza A subtype H1N1 and/or SARS-
-CoV2. Moreover, treatment with steroids can 
potentially lead to an increase in the number of 
opportunistic and superimposed infections and 
needs to be cautiously administered in the subset 
of COVID-19 patients requiring oxygen support 
and/or in patients with ARDS. Our study did 
not find any difference in mortality despite the 
availability of treatment for H1N1 influenza in 
advanced stages of the disease and despite the use 
of steroids in COVID-19. Hence, we recommend 
implementing and using strategies focusing on 
prevention for influenza (i.e. immunization) and 
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